Goodbye Nvidia, Hello Microsoft: Halvorsen's Big Q3 Hedge Fund Pivot - DraftKings ( NASDAQ:DKNG ) , Microsoft ( NASDAQ:MSFT ) , NVIDIA ( NASDAQ:NVDA ) , PNC Financial Services Gr ( NYSE:PNC )
Andreas Halvorsen just reminded Wall Street why Viking Global Investors is one of the hedge fund world's most-watched portfolios: he doesn't trim, he swings.
Do Options Traders Know Something About Edwards Lifesciences Stock We Don't?
Investors need to pay close attention to EW stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Edwards Lifesciences Stock?
Investors need to pay close attention to EW stock based on the movements in the options market lately.
Here's How Much $100 Invested In Edwards Lifesciences 20 Years Ago Would Be Worth Today - Edwards Lifesciences ( NYSE:EW )
Edwards Lifesciences ( NYSE:EW ) has outperformed the market over the past 20 years by 8.36% on an annualized basis producing an average annual return of 17.21%. Currently, Edwards Lifesciences has a market capitalization of $49.40 billion.
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.
EW Stock Gains on Q3 Earnings and Revenue Beat, Margins Crash
Edwards Lifesciences Q3 earnings and sales beat estimates on robust TAVR and TMTT growth, though margins take a sharp hit.
Nvidia To Rally Around 37%? Here Are 10 Top Analyst Forecasts For Wednesday - Apple ( NASDAQ:AAPL ) , Cheesecake Factory ( NASDAQ:CAKE )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Rosenblatt cut Stagwell Inc. ( NASDAQ:STGW ) price target from $10 to $9.
This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Edwards Lifesciences ( NYSE:EW ) , Brookfield Infr Partners ( NYSE:BIP )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Exploring Analyst Estimates for Edwards Lifesciences ( EW ) Q3 Earnings, Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Idexx Laboratories ( IDXX ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EW Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation - EW
New York, New York-- ( Newsfile Corp. - October 23, 2025 ) - Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation ( NYSE: EW ) .
Will SYK's Q3 Results Reflect MedSurg Strength & Rebound in Orthopaedics?
Stryker's Q3 results are expected to highlight MedSurg strength and solid robotics-led growth in Orthopaedics, partly offset by tariff headwinds.
Will RVTY Q3 Earnings Reflect Segmental Strength Amid Rising Demand?
RVTY's third-quarter results are likely to reflect strong performance in the Life Sciences segment. However, the Diagnostic segment is set to face challenges in China.
WST Q3 Earnings Preview: Can GLP-1 Momentum Outweigh Margin Pressure?
West Pharma's Q3 numbers hinge on robust GLP-1 and biologics demand, but labor constraints, tariffs, and plant shutdowns could test its margin resilience.
Robust TAVR Growth to Drive Edwards Lifesciences' Q3 Earnings
Strong TAVR demand and expanding valve therapies are set to power EW's Q3 results despite lower EPS estimates.
Pulse Biosciences Unveils Promising First-in-Human Data for nPulse
PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.
Here's How Much $100 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth Today - Edwards Lifesciences ( NYSE:EW )
Edwards Lifesciences ( NYSE:EW ) has outperformed the market over the past 15 years by 1.34% on an annualized basis producing an average annual return of 13.44%. Currently, Edwards Lifesciences has a market capitalization of $43.41 billion.
Abbott to Report Q3 Earnings: Medical Devices Arm in Focus
ABT's Q3 results may show strength in Medical Devices and Nutrition, offsetting softness in Diagnostics.
TLRY Gears Up to Report Q1 Earnings: Cannabis Recovery in Focus
Tilray Brands' fiscal first-quarter report is likely to highlight international cannabis gains, European expansion and wellness growth.
EW Investor News: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation - EW - Edwards Lifesciences ( NYSE:EW )
NEW YORK, Oct. 08, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation ( NYSE:EW ) .
AngioDynamics ( ANGO ) Reports Q1 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) delivered earnings and revenue surprises of +28.57% and +4.75%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
Here's How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 20 Years - Edwards Lifesciences ( NYSE:EW )
Edwards Lifesciences ( NYSE: EW ) has outperformed the market over the past 20 years by 7.57% on an annualized basis producing an average annual return of 16.53%. Currently, Edwards Lifesciences has a market capitalization of $45.32 billion.
EW Investor News: If You Have Suffered Losses in Edwards Lifesciences Corporation ( NYSE: EW ) , You Are Encouraged to Contact The Rosen Law Firm About Your Rights - Edwards Lifesciences ( NYSE:EW )
NEW YORK, Sept. 26, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation ( NYSE: EW ) .
SoCalBio Investor Conference Sessions to Spotlight Bioscience Workforce Development, Technology Transfer, and AI-Driven Innovation
LOS ANGELES, Sept. 25, 2025 ( GLOBE NEWSWIRE ) -- The Southern California Biomedical Council ( SoCalBio ) today announced the final lineup of expert panels for its 27th Annual Investor & Partnership Conference, taking place October 1-2 at the Hyatt Regency Newport Beach.
EDWARDS ( EW ) ALERT: Bragar Eagel & Squire, P.C. is Investigating Edwards Lifesciences Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Edwards Lifesciences ( NYSE:EW )
Bragar Eagel & Squire, P.C. Litigation Partners Encourage Investors Who Suffered Losses In Edwards ( EW ) To Contact Him Directly To Discuss Their Options
Picard Announces Appointment of Two New Members to its Board of Directors
Appointments strengthen Picard's Board with proven expertise in capital markets and global MedTech leadership Appointments strengthen Picard's Board with proven expertise in capital markets and global MedTech leadership ...
Here Are Billionaire Ken Griffin's 5 Biggest Stock Holdings
One was recently acquired by a much bigger company.
ABT vs. EW: Which Structural Heart Device Stock Is Worth Buying Now?
As the structural heart market expands, Abbott and Edwards battle for leadership. Which stock holds stronger growth momentum now?
Israel Englander's Millennium Goes All-In On Crypto And Healthcare While Rebalancing Big Tech Bets: Bitcoin ETF And Palantir Stakes Soar In Q2 - iShares Bitcoin Trust ( NASDAQ:IBIT ) , Palantir Technologies ( NASDAQ:PLTR )
Millennium Management LLC, led by billionaire Israel Englander, made bold moves in its portfolio according to its second-quarter 13F filings, significantly boosting exposure to cryptocurrency and healthcare while strategically rebalancing its big tech holdings.
Octane to Host Cardiovascular Tech Forum 2025 on September 11-12 in Newport Beach, California
NEWPORT BEACH, Calif., Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- via InvestorWire -- Octane, an innovative organization building the SoCal of Tomorrow by connecting people, resources, and capital to fuel technology growth in Southern California, is pleased to announce that the Octane Cardiovascular ...
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today - Edwards Lifesciences ( NYSE:EW )
Edwards Lifesciences EW has outperformed the market over the past 15 years by 2.56% on an annualized basis producing an average annual return of 15.33%. Currently, Edwards Lifesciences has a market capitalization of $47.73 billion.
Edwards Lifesciences Corporation Investors: Company Investigated by the Portnoy Law Firm - Edwards Lifesciences ( NYSE:EW )
Investors can contact the law firm at no cost to learn more about recovering their losses
Abbott Taps Growing TMVR Market With Tendyne System
ABT wins FDA nod for its Tendyne TMVR system, offering a minimally invasive option for patients with severe mitral valve disease.
EDWARDS ( EW ) ALERT: Bragar Eagel & Squire, P.C. is Investigating Edwards Lifesciences Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Edwards Lifesciences ( NYSE:EW )
Bragar Eagel & Squire, P.C. Litigation Partners Encourage Investors Who Suffered Losses In Edwards ( EW ) To Contact Him Directly To Discuss Their Options
Here Are Billionaire Ken Griffin's 5 Biggest Stock Holdings
A longtime leader in financial services tops the list.
Deal Dispatch: Performance Food Rejects Offer, Claire's Bankrupt - American Woodmark ( NASDAQ:AMWD ) , Boeing ( NYSE:BA )
Performance Food rejects offer; Bachan's, Hg and Yomeishu explore sales; Lufthansa drops Air Europa bid; NFL sells media to ESPN Skydance Media finally completed its $8-billion acquisition of Paramount Global. Sen. Warren called it a "wink, wink" arrangement.
Pediatrix Medical's Q2 Earnings Beat on Strong Patient Volumes
MD's Q2 earnings benefit from higher patient volumes and a declining expense level. It now projects 2025 adjusted EBITDA within $245-$255 million, up from the prior view of $220-$240 million.
FTC Sounds Alarm On Edwards' Heart Device, M&A Attempt - Edwards Lifesciences ( NYSE:EW )
FTC says Edwards' JenaValve deal would eliminate the only U.S. competition in TAVR-AR devices Despite FTC action, Edwards lifts 2025 adjusted EPS guidance to the high-end of $2.45-$2.55 per share. The market's back, and these 3 income stocks are thriving. See them here→
PROCEPT BioRobotics ( PRCT ) Earnings Transcript
Image source: The Motley Fool.Aug. 6, 2025, 8:30 p.m. ETChief Executive Officer - Reza ZadnoContinue reading ...
JenaValve Responds to FTC's Action Against Proposed Edwards Lifesciences Acquisition
IRVINE, Calif., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- JenaValve Technology announced today that the U.S. Federal Trade Commission ( FTC ) moved to block the company's proposed acquisition by Edwards Lifesciences. JenaValve respectfully disagrees with the FTC's decision and remains committed ...
Edwards Lifesciences Stock: Likely To See Sluggish Price Action Through 2027 - Edwards Lifesciences ( NYSE:EW )
Edwards Lifesciences EW has just entered Phase 18, the final stage of its 18-phase Adhishthana cycle on the weekly chart. While the stock's setup doesn't necessarily point to a bearish outlook, the structure suggests that sluggish, range-bound price action could dominate through early 2027.
Edwards Lifesciences ( EW ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, July 24, 2025, at 5 p.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
ENSG's Q2 Earnings Beat on Higher Occupancy Rates, Stock Up 9%
Ensign Group's Q2 earnings improve 20.5% year over year, fueled by stronger occupancy, patient days and rental revenues.
Edwards Lifesciences Q2 Earnings - Edwards Lifesciences ( NYSE:EW )
Q2 sales hit $1.53 billion vs. $1.49 billion est., EPS at $0.67 vs. $0.62 est.; TAVR up 8.9%, TMTT up 61.9%. FY25 sales outlook raised to $5.90 billion-$6.10 billion; Goldman lifts price target to $101 on growth momentum. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
US Stocks Hit New Highs As Magnificent Seven Reach $19 Trillion - AutoNation ( NYSE:AN )
Nvidia hits $4.25 trillion market cap; Magnificent Seven now worth $19 trillion combined. Bitcoin falls toward $115,800, on track for the second straight weekly loss for the first time since March 2025. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
HCA Beats Q2 Earnings on Higher Admissions, Ups '25 EPS View
HCA Healthcare's Q2 earnings rose 24% year over year on stronger patient volumes. EPS for 2025 is expected to be within $25.5-$27, up from the earlier view of $24.05-$25.85.
Edwards Lifesciences Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Results - Edwards Lifesciences ( NYSE:EW )
Edwards Lifesciences Corporation EW reported better-than-expected second-quarter financial results on Thursday. Edwards Lifesciences posted adjusted earnings of 67 cents per share, beating market estimates of 62 cents per share. The company's quarterly sales came in at $1.532 billion versus ...
EW Stock Climbs on Q2 Earnings & Revenue Beat, Margins Down
Edwards Lifesciences posts a second-quarter 2025 earnings and revenue beat, with strong growth in TAVR and TMTT segments despite margin pressure.
PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO
SAN JOSE, Calif., July 24, 2025 ( GLOBE NEWSWIRE ) -- PROCEPT BioRobotics ( Nasdaq: PRCT ) ( "the Company" ) , a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that Larry L.
PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO - PROCEPT BioRobotics ( NASDAQ:PRCT )
Larry L. Wood to join PROCEPT BioRobotics effective September 2, 2025 Company confirms strong underlying business trends and pre-announces 2Q25 revenue of approximately $79.2 million, representing annual growth of 48%
